milvexian
bms
['milvexian']
while the therapy, milvexian, showed a 30% risk reduction in recurrent ischemic strokes among people who showed symptoms, it didn't have an effect on covert infarcts, eroding investor confidence. 
The world's premier investing publication since 1921.
For customer support, visit https://t.co/HkyUtq6BNr